Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
FreeMind Investments (FMI) is a venture capital fund established to focus on the life sciences industry. Founded in Boston, Massachusetts, FMI collaborates with strategic and limited partners to invest in research and development (R&D) initiatives. The organization benefits from the expertise of FreeMind Group and Daewoong Pharma, which enhances its data-driven investment model and provides access to various pharmaceutical deal-making opportunities. FMI operates additional offices in Jerusalem, Israel, and Seoul, South Korea, showcasing its global reach.
Currently, FMI manages a diverse portfolio of investments and has established a reputation for its rigorous due diligence process. The firm primarily targets companies in the pre-clinical and clinical stages of development, aiming to identify high-potential firms for successful exits. FMI's notable milestones include its strategic partnerships and its commitment to advancing the life sciences sector through targeted investments.
FreeMind Investments primarily invests in the life sciences sector, with a strong emphasis on companies at various stages of development, particularly pre-clinical and clinical stage programs. The organization employs a proprietary investment formula that rigorously assesses both scientific and business potential through comprehensive due diligence. FMI's geographic focus is predominantly on the United States (60%), followed by Europe (30%), and other regions such as Israel, Australia, and Canada (10%).
The firm seeks to identify companies with a high likelihood of successful exits, including initial public offerings (IPOs) or mergers and acquisitions (M&A). FMI's investment strategy is characterized by its commitment to understanding the complexities of the life sciences industry, which allows it to make informed decisions that align with its investment thesis.
FreeMind Investments boasts a diverse portfolio of notable companies within the life sciences sector:
Ram May-Ron: Founder & Managing Partner. Ram has extensive experience in venture capital and life sciences, having led numerous successful investments in the sector.
B. Christopher Kim: Co-Founder & Venture Partner. Christopher brings a wealth of knowledge in biotech investments and has a strong track record in identifying high-potential companies.
Ayal Ronen: Director. Ayal has a background in life sciences and plays a key role in the firm's investment strategy and due diligence processes.
Alexandra Duev-Cohen: Principal. Alexandra focuses on sourcing and evaluating investment opportunities within the life sciences sector.
Jonathan Adalist: Principal. Jonathan specializes in operational support for portfolio companies, leveraging his expertise in the biotech industry.
Michal Fefferman: Head of Operations. Michal oversees the firm's operational activities, ensuring efficient processes and support for portfolio companies.
To pitch FreeMind Investments, startups should send an email to info@freemindinvestments.com. The pitch deck should include a clear overview of the business model, market opportunity, and scientific validation. FMI prefers concise presentations that highlight key metrics and milestones.
Startups should expect a response within a few weeks, and while warm introductions are appreciated, they are not mandatory. Clear communication and a well-structured pitch can significantly enhance the chances of engagement.
As of October 2023, FreeMind Investments continues to expand its portfolio in the life sciences sector, focusing on companies that demonstrate strong scientific and business potential. The firm has recently engaged in discussions with several promising startups in the biotech space, aiming to identify new investment opportunities.
FMI remains active in its existing portfolio, providing ongoing support and resources to its companies as they navigate the complexities of the life sciences industry. The firm is committed to fostering growth and innovation within its portfolio, ensuring that its investments align with its strategic focus on high-potential life sciences companies.
What are FreeMind Investments' investment criteria?
FMI focuses on the life sciences sector, particularly companies in pre-clinical and clinical stages. The firm employs a rigorous due diligence process to assess scientific and business potential.
How can startups apply or pitch to FreeMind Investments?
Startups can reach out via email at info@freemindinvestments.com to initiate discussions regarding potential investments.
What makes FreeMind Investments different from other venture capital firms?
FMI leverages the expertise of FreeMind Group and Daewoong Pharma, providing a data-driven investment model and access to pharmaceutical deal-making opportunities.
What is the geographic scope of FreeMind Investments?
FMI primarily invests in the United States (60%), Europe (30%), and other regions, including Israel, Australia, and Canada (10%).
What is the typical check size for investments?
While specific check sizes are not disclosed, FMI targets companies at various stages, indicating flexibility in investment amounts based on the company's needs and potential.
What is FreeMind Investments' post-investment involvement like?
FMI actively engages with its portfolio companies, providing operational support and leveraging its network to assist in navigating the complexities of the life sciences industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.